Viral Hepatitis

You have full text access to this OnlineOpen article

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C†

  1. Véronique Loustaud-Ratti1,‡,*,
  2. Sophie Alain2,
  3. Annick Rousseau3,
  4. Isabelle Fouchard Hubert4,
  5. François Ludovic Sauvage3,
  6. Pierre Marquet3,
  7. François Denis2,
  8. Françoise Lunel5,
  9. Paul Calès4,
  10. Annie Lefebvre1,
  11. Anne-Laure Fauchais1,
  12. Eric Liozon1,
  13. Elisabeth Vidal1

Article first published online: 14 JAN 2008

DOI: 10.1002/hep.22217

Issue

Hepatology

Hepatology

Volume 47, Issue 5, pages 1453–1461, May 2008

Additional Information

How to Cite

Loustaud-Ratti, V., Alain, S., Rousseau, A., Hubert, I. F., Sauvage, F. L., Marquet, P., Denis, F., Lunel, F., Calès, P., Lefebvre, A., Fauchais, A.-L., Liozon, E. and Vidal, E. (2008), Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology, 47: 1453–1461. doi: 10.1002/hep.22217

Author Information

  1. 1

    Centre Hospitalier Universitaire (CHU) Limoges, Internal Medicine Department, Limoges, France

  2. 2

    CHU Limoges, Université Limoges, Virology Department, EA3175 Avenir INSERM, Limoges, France

  3. 3

    CHU Limoges, Université Limoges, INSERM Unité 850, Limoges, France

  4. 4

    CHU Angers, Department of Hepatogastroenterology, Angers, France

  5. 5

    CHU Angers, Department of Virology, Angers, France

  1. ‡

    fax: +33(0)5 55 05 67 67.

*Internal Medicine Department, CHU Limoges, 2, avenue Martin Luther King, 87042 Limoges Cedex, France

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 24 APR 2008
  2. Article first published online: 14 JAN 2008
  3. Accepted manuscript online: 14 JAN 2008 12:00AM EST
  4. Manuscript Accepted: 20 DEC 2007
  5. Manuscript Received: 11 JUL 2007

Funded by

  • Centre Hospitalier Universitaire de Limoges
  • Roche, France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (367K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Girish S Naik, Manoj G Tyagi, A Pharmacological Profile of Ribavirin and Monitoring of its Plasma Concentration in Chronic Hepatitis C Infection, Journal of Clinical and Experimental Hepatology, 2012, 2, 1, 42

    CrossRef

  2. 2
    F. Stickel, B. Helbling, M. Heim, A. Geier, C. Hirschi, B. Terziroli, K. Wehr, A. De Gottardi, F. Negro, T. Gerlach, Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 2
    Direct Link:
  3. 3
    Antonio DʼAvolio, Alessia Ciancio, Marco Siccardi, Antonina Smedile, Lorena Baietto, Marco Simiele, Diego Aguilar Marucco, Giuseppe Cariti, Andrea Calcagno, Daniel Gonzalez de Requena, Mauro Sciandra, Jessica Cusato, Giulia Troshina, Stefano Bonora, Mario Rizzetto, Giovanni Di Perri, Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment, Therapeutic Drug Monitoring, 2012, 34, 2, 165

    CrossRef

  4. 4
    Paloma Muñoz- de-Rueda, Angeles Ruiz-Extremera, Jose M. Candel, Rosa Quiles, Ana Belen Martín, Moises Diago, Raul Andrade, Jose M. Navarro, Ana Gila, Josefa León, Angel Carazo, Dolores Quintero, Javier Salmerón, Plasma Ribavirin Trough Concentrations During Treatment of Chronic Hepatitis C in Genotype-1 Patients, Journal of Clinical Gastroenterology, 2012, 46, 4, 328

    CrossRef

  5. 5
    Runyan Jin, Michael J. Fossler, John G. McHutchison, Charles D. Howell, Thomas C. Dowling, Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Infection, The AAPS Journal, 2012,

    CrossRef

  6. 6
    Stanislas Pol, Hélène Fontaine, Traitements personnalisés du virus de l’hépatite C, La Presse Médicale, 2012, 41, 2, 146

    CrossRef

  7. 7
    Takeshi Nishimura, Kanji Yamaguchi, Hiroaki Hashimoto, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Masafumi Sakamoto, Naoki Ohnish, Yasuyuki Nagao, Mika Okita, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh, Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy, Hepatology Research, 2012, 42, 6
    Direct Link:
  8. You have free access to this content8
    P. Deltenre, C. Moreno, A. Tran, I. Ollivier, F. Provôt, F. Stanke, M. Lazrek, H. Castel, V. Canva, A. Louvet, M. Colin, F. Glowacki, S. Dharancy, J. Henrion, M. Hazzan, C. Noel, P. Mathurin, Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy, Alimentary Pharmacology & Therapeutics, 2011, 34, 4
    Direct Link:
  9. 9
    Nanna Hansen, Niels Obel, Peer B Christensen, Mette Kjær, Alex L Laursen, Henrik B Krarup, Axel Møller, Poul Schlichting, Jens Bukh, Nina Weis, Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study, BMC Infectious Diseases, 2011, 11, 1, 177

    CrossRef

  10. 10
    F. Nicot, L. Alric, K. Barange, S. Métivier, J.M. Dramard, J.M. Combis, B. Castan, J.J. Meurisse, J.L. Payen, D. Garipuy, H. Desmorat, J.M. Peron, S. Thebault, T. Morin, C. Renou, P. Barel, B. Guerin, Y. Imbert, S. Sire, K. Sauné, E. Chatelut, J. Izopet, Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy, Journal of Medical Virology, 2011, 83, 3
    Direct Link:
  11. 11
    Caroline Solas, Maxime Paré, Sylvie Quaranta, Françoise Stanke-Labesque, Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine, Thérapie, 2011, 66, 3, 221

    CrossRef

  12. 12
    J. Ashby, L. Garvey, O. W. Erlwein, H. Lamba, R. Weston, K. Legg, N. Latch, M. O. McClure, L. Dickinson, A. D'Avolio, D. Back, A. Winston, Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers, Journal of Antimicrobial Chemotherapy, 2011, 66, 6, 1340

    CrossRef

  13. 13
    Véronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, Marianne Maynard, Gérard Babany, Sophie Alain, Christian Trépo, Victor De Ledinghen, Marc Bourlière, Stanislas Pol, Vincent Di Martino, Jean-Pierre Zarski, Alexandrina Pinta, Denis Sautereau, Pierre Marquet, Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment, Digestive and Liver Disease, 2011, 43, 11, 850

    CrossRef

  14. 14
    N. Furusyo, M. Murata, E. Ogawa, K. Toyoda, T. Ihara, H. Ikezaki, T. Hayashi, T. Koga, M. Kainuma, J. Hayashi, Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response, Journal of Antimicrobial Chemotherapy, 2011, 66, 5, 1127

    CrossRef

  15. 15
    C. Pedersen, Å. Alsiö, M. Lagging, N. Langeland, M. Färkkilä, M. Rauning Buhl, K. Mørch, J. Westin, P. Sangfelt, G. Norkrans, P. Brehm Christensen, Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection, Journal of Viral Hepatitis, 2011, 18, 4
    Direct Link:
  16. 16
    Serena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, Clemens Richter, Peter P Koopmans, Corrien P W G M Verwey-Van Wissen, Joost P H Drenth, David M Burger, Ribavirin Plasma Concentration Measurements in Patients With Hepatitis C: Early Ribavirin Concentrations Predict Steady-State Concentrations, Therapeutic Drug Monitoring, 2011, 33, 1, 40

    CrossRef

  17. 17
    T. Witthoeft, D. Hueppe, C. John, J. Goelz, R. Heyne, B. Moeller, G. Teuber, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, G. Moog, N. Dikopoulos, S. Mauss, Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study, Journal of Viral Hepatitis, 2010, 17, 7
    Direct Link:
  18. 18
    Mark S. Sulkowski, Mitchell L. Shiffman, Nezam H. Afdhal, K. Rajender Reddy, Jonathan McCone, William M. Lee, Steven K. Herrine, Stephen A. Harrison, F. Fred Poordad, Kenneth Koury, Weiping Deng, Stephanie Noviello, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, 2010, 139, 5, 1602

    CrossRef

  19. 19
    Françoise Stanke-Labesque, Véronique Loustaud-Ratti, Gérard Babany, Marie-Claude Gagnieu, Pierre Marquet, Ribavirin therapeutic drug monitoring: why, when and how?, Fundamental & Clinical Pharmacology, 2010, 24, 4
    Direct Link:
  20. 20
    Mamta K Jain, Cindy Zoellner, Role of ribavirin in HCV treatment response: now and in the future, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 673

    CrossRef

  21. 21
    Pierre Marquet, François-Ludovic Sauvage, Véronique Loustaud-Ratti, Gérard Babany, Annick Rousseau, Gérard Lachâtre, Stability of Ribavirin Concentrations Depending on the Type of Blood Collection Tube and Preanalytical Conditions, Therapeutic Drug Monitoring, 2010, 1

    CrossRef

  22. 22
    Tarik Asselah, Eric Pasmant, Saïd Lyoumi, Unraveling the genetic predisposition of ribavirin-induced anaemia, Journal of Hepatology, 2010, 53, 5, 971

    CrossRef

  23. 23
    Erik De Clercq, Another ten stories in antiviral drug discovery (part C): “Old” and “new” antivirals, strategies, and perspectives, Medicinal Research Reviews, 2009, 29, 4
    Direct Link:
  24. 24
    Francois-Ludovic Sauvage, Francoise Stanke-Labesque, Marie-Claude Gagnieu, Jean-Francois Jourdil, Gerard Babany, Pierre Marquet, Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C, Therapeutic Drug Monitoring, 2009, 31, 3, 374

    CrossRef

  25. 25
    D. BREILH, J. FOUCHER, L. CASTÉRA, P. TRIMOULET, S. DJABAROUTI, W. MERROUCHE, P. COUZIGOU, M.-C. SAUX, V. DE LÉDINGHEN, Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2009, 30, 5
    Direct Link:
  26. 26
    V. Loustaud-Ratti, F. Stanke-Labesque, P. Marquet, M.-C. Gagnieu, M. Maynard, G. Babany, C. Trépo, Optimizing ribavirin dosage: A new challenge to improve treatment efficacy in genotype 1 hepatitis C patients, Gastroentérologie Clinique et Biologique, 2009, 33, 6-7, 580

    CrossRef

  27. 27
    Catherine François, Sandrine Castelain, Gilles Duverlie, Dominique Capron, Eric Nguyen-Khac, Optimizing the treatment of chronic viral hepatitis C, Expert Review of Gastroenterology & Hepatology, 2009, 3, 6, 607

    CrossRef

  28. 28
    Véronique Loustaud-Ratti, Annick Rousseau, Pierre Marquet, François Denis, Sophie Alain, Ribavirin in chronic hepatitis C: past and future, Expert Review of Anti-infective Therapy, 2009, 7, 3, 249

    CrossRef

  29. 29
    Dominique Breilh, Sarah Djabarouti, Pascale Trimoulet, Brigitte Le Bail, Michel Dupon, Jean-Marie Ragnaud, Hervé Fleury, Marie-Claude Saux, Rodolphe Thiébaut, Geneviève Chêne, Didier Neau, Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIV-Coinfected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009, 52, 3, 428

    CrossRef

  30. 30
    H. Le Guillou-Guillemette, P. Calès, F. Lunel, Actualités sur les co-infections VIH–VHC, Antibiotiques, 2008, 10, 4, 167

    CrossRef

  31. 31
    Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Yen Hsieh, Ming-Lung Yu, Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure, Hepatology, 2008, 48, 2
    Direct Link:
  32. 32
    Ming-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure, Hepatology, 2008, 48, 3
    Direct Link:
  33. 33
    Wolf Peter Hofmann, Eva Herrmann, Christoph Sarrazin, Stefan Zeuzem, Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms, Liver International, 2008, 28, 10
    Direct Link:
  34. 34
    J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, V. Soriano, Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C, Journal of Antimicrobial Chemotherapy, 2008, 62, 6, 1174

    CrossRef

View Full Article (HTML) Get PDF (367K)